An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.

Inhibitors of the protease of HIV-1 have been used successfully for the treatment of HIV-1-infected patients and AIDS disease. We tested whether these protease inhibitory drugs exerted effects in addition to their antiviral activity. Here, we show in mice infected with lymphocytic choriomeningitis v...

Bibliográfalaš dieđut
Váldodahkkit:	André, P, Groettrup, M, Klenerman, P, de Giuli, R, Booth, B, Cerundolo, V, Bonneville, M, Jotereau, F, Zinkernagel, R, Lotteau, V
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	1998

Geahča maid

Role of the proteasome and non proteasomal proteases in the generation of CTL epitopes.
Dahkki: Cerundolo, V, et al.
Almmustuhtton: (1998)

Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes.
Dahkki: Kelleher, A, et al.
Almmustuhtton: (2001)

Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
Dahkki: Gileadi, U, et al.
Almmustuhtton: (1999)

Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes.
Dahkki: Klenerman, P, et al.
Almmustuhtton: (1998)

The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response
Dahkki: Anjali K. Gupta, et al.
Almmustuhtton: (2007-04-01)

CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef.
Dahkki: Milicic, A, et al.
Almmustuhtton: (2005)

Competitive Metabolite Profiling of Natural Products Reveals Subunit Specific Inhibitors of the 20S Proteasome
Dahkki: Atul Pawar, et al.
Almmustuhtton: (2020-01-01)

Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3.
Dahkki: Valmori, D, et al.
Almmustuhtton: (1999)

Computational investigations of HIV-1 protease and protease inhibitors interactions
Dahkki: Sham, Hoi Fung
Almmustuhtton: (2014)

The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells.
Dahkki: Cerundolo, V, et al.
Almmustuhtton: (1997)

Current and Novel Inhibitors of HIV Protease
Dahkki: Jan Konvalinka, et al.
Almmustuhtton: (2009-12-01)

Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation.
Dahkki: Johanna Bialas, et al.
Almmustuhtton: (2015-01-01)

Alteration of HIV epitope processing and presentation by HIV protease inhibitors
Dahkki: Kourjian G, et al.
Almmustuhtton: (2012-09-01)

Additivity in the Analysis and Design of HIV Protease Inhibitors
Dahkki: Jorissen, Robert N., et al.
Almmustuhtton: (2012)

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION
Dahkki: V.B. Denisenko, et al.
Almmustuhtton: (2010-02-01)

PRACTICE OF USING VIRAL PROTEASE INHIBITORS IN CHILDREN WITH HIV INFECTION
Dahkki: V.B. Denisenko, et al.
Almmustuhtton: (2010-02-01)

Proteasome inhibitors as anti-cancer agents.
Dahkki: Murray, R, et al.
Almmustuhtton: (2000)

Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.
Dahkki: Valmori, D, et al.
Almmustuhtton: (1999)

Down-regulation of Akt signaling with HIV-1 protease inhibitors
Dahkki: Gupta, A, et al.
Almmustuhtton: (2005)

Effects of an anticarcinogenic Bowman-Birk protease inhibitor on purified 20S proteasome and MCF-7 breast cancer cells.
Dahkki: Larissa da Costa Souza, et al.
Almmustuhtton: (2014-01-01)

New proteasome inhibitors in the management of multiple myeloma
Dahkki: S. V. Semochkin
Almmustuhtton: (2019-07-01)

MAPPING OF PATENTS RELATED TO PROTEASE INHIBITORS AND HIV
Dahkki: Romério Rodrigues dos Santos Silva, et al.
Almmustuhtton: (2022-04-01)

Role of Gag in HIV Resistance to Protease Inhibitors
Dahkki: Fabrizio Mammano, et al.
Almmustuhtton: (2010-07-01)

Two Novel Precursors of the HIV-1 Protease Inhibitor Darunavir Target the UPR/Proteasome System in Human Hepatocellular Carcinoma Cell Line HepG2
Dahkki: Roberta Rinaldi, et al.
Almmustuhtton: (2021-11-01)

TRIM5α Restricts Flavivirus Replication by Targeting the Viral Protease for Proteasomal Degradation
Dahkki: Abhilash I. Chiramel, et al.
Almmustuhtton: (2019-06-01)

Site-Specific Proteasome Inhibitors
Dahkki: Alexei F. Kisselev
Almmustuhtton: (2021-12-01)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
Dahkki: Noah M. Merin, et al.
Almmustuhtton: (2014-12-01)

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Dahkki: Christoph Driessen, et al.
Almmustuhtton: (2016-03-01)

Human T-cell leukemia virus type 1 Tax protein binds to assembled nuclear proteasomes and enhances their proteolytic activity.
Dahkki: Hemelaar, J, et al.
Almmustuhtton: (2001)

The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors
Dahkki: Nathalie Vigneron, et al.
Almmustuhtton: (2015-09-01)

Evaluation of COVID-19 protease and HIV inhibitors interactions
Dahkki: Tran Linh, et al.
Almmustuhtton: (2022-03-01)

Safety of protease inhibitors in HIV-infected pregnant women
Dahkki: Chougrani I, et al.
Almmustuhtton: (2013-09-01)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
Dahkki: Kathleen M S E Reyskens, et al.
Almmustuhtton: (2013-01-01)

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
Dahkki: Konvalinka Jan, et al.
Almmustuhtton: (2011-08-01)

Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study
Dahkki: Kann G, et al.
Almmustuhtton: (2021-08-01)

Immune surveillance and AIDS progression.
Dahkki: Zinkernagel, R, et al.
Almmustuhtton: (1997)

Correspondence - Immune surveillance and AIDS progression
Dahkki: Zinkernagel, R, et al.
Almmustuhtton: (1997)

Of mice and men: cytotoxic T cells and AIDS pathogenesis.
Dahkki: Klenerman, P, et al.
Almmustuhtton: (1999)

What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus?
Dahkki: Klenerman, P, et al.
Almmustuhtton: (1997)

Resistance associated mutations to protease inhibitors on HIV-2 infected patients in Portugal
Dahkki: J. Lopes, et al.
Almmustuhtton: (2021-04-01)